2024 UK Sexually-Transmitted Disease (STD) Molecular Diagnostics Market: Shares and Segment Forecasts--Chancroid, Chlamydia, Gonorrhea, Herpes (I/II, VI), Papillomavirus (Pap Smear, HPV), Syphilis

August 2024 | - | ID: 2728864D6F44EN
Venture Planning Group

Abstracts

About This Report This new report from LeadingMarketResearch.com presents detailed analysis of the U.K. STD market. Current scientific views on epidemiology and etiology are presented for:AIDS/HIV
Chancroid
Chlamydia
Gonorrhea
Granuloma Inguinale
Herpes I/II
Lymphogranuloma
Mycoplasma
Papillomavirus
Syphilis
Trichomonas VaginalisThe report provides test volume and sales projections for:- Hospitals
- Commercial/Private Labs
- Public Health Labs
The report is available by section, and can be customized to specific information needs and budget.In addition to market share and sales forecasts, the report:- Examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies; - Reviews features and operating characteristics of major analyzers used for STD testing;- Profiles key suppliers and potential market entrants developing innovative technologies and products; and- Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues.Methodology The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products.In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as LeadingMarketResearch's proprietary data files was conducted.

Contents

I. Introduction
II. Worldwide Market and Technology Overview
A. Major STD Tests

1. AIDS/HIV

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

2. CHANCROID

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

3. CHLAMYDIA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

4. GONORRHEA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

5. GRANULOMA INGUINALE

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

6. HERPES SIMPLEX VIRUS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

7. LYMPHOGRANULOMA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

8. MYCOPLASMA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

9. PAPILLOMAVIRUSES

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
Table of Contents (continued)

10. SYPHILIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

11. TRICHOMONAS VAGINALIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
B. Instrumentation Review
C. Emerging Diagnostic Technologies
III. Country Test Volume and Sales Forecasts,
Supplier Shares
IV. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized
Testing Markets

1. MARKETING APPROACHES

2. PRODUCT COMPLEXITY

3. CUSTOMER PREFERENCE

4. ESTABLISHED SUPPLIERS

5. EMERGING SUPPLIERS

6. MAJOR TYPES OF DISTRIBUTORS

7. MARKET SEGMENTATION

V. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges